In Pursuit of Total Brain Health(TM) and Pharmaceutically Green(TM) Solutions
Lucid Psycheceuticals - developing novel therapeutic solutions for neuro and inflammatory disorders
Our team is developing novel therapeutic solutions for unmet clinical challenges, and we are focused on small molecule drugs. Our team is composed of highly specialized science experts focused on providing leading edge therapeutics in the areas of inflammatory disorders, neurodegenerative disorders and mental health.
Lucid's team has shortlisted Lucid-201, a known molecule with clinical proof of efficacy in major depressive disorder (MDD) and related psychiatric conditions.
Lucid completed the acquisition of exclusive world-wide license to new chemical entities (NCEs), associated patents and preclinical efficacy data from University Health Network (UHN, Toronto, Canada) in May 2021.
Lucid Psycheceuticals is a wholly-owned subsidiary of FSD Pharma, Inc. (HUGE), a publicly-traded company.